Drug Pipeline & Clinical Update - February 2026
.jpg)
Highlights
- 2 key new drug approvals, including Adquey™ for the treatment of mild to moderate atopic dermatitis in patients 2 years of age and older
- 4 notable expanded indications, including Wakix® (pitolisant) to treat cataplexy in patients 6 years of age and older with narcolepsy
- 2 new generic launches, including Pomalyst® (pomalidomide) oral capsule
- Capital Rx's updated drug recall report: CLICK HERE to review.
-
Judi Health closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications and products in the pipeline. Please find the February 2026 Monthly Drug Update below:
Key New Drug Approvals
Yuvezzi™ (carbachol; brimonidine) ophthalmic solution
Approval Date: 01/28/2026
Indication: Treatment of presbyopia in adults
Cost*: TBD
Key Consideration:
- First and only dual-agent FDA-approved for presbyopia
- Administered as 1 drop in each eye daily, with effects lasting up to 10 hours
- Expected to be available in the second quarter of 2026
Press Release: Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZITM, the First and Only Combination Eye Drop Approved to Treat Presbyopia
Adquey™ (difamilast) ointment
Approval Date: 02/12/2026
Indication: Treatment of mild to moderate atopic dermatitis in patients 2 years of age and older
Cost*: TBD
Key Consideration:
- Non-steroidal, topical phosphodiesterase 4 (PDE4) inhibitor
- Recommended dose is applied to affected area(s) twice daily
Press Release: With FDA approval, Adquey Becomes Newest Topical PDE4 Inhibitor for AD
Notable Expanded Indications
- Noxafil® (posaconazole) – expanded to treat invasive aspergillosis in patients 2 years of age and older, weighing at least 10 kg
- Wakix® (pitolisant) – expanded to treat cataplexy in patients 6 years of age and older with narcolepsy
- Calquence® (acalabrutinib) – expanded to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in combination with venetoclax
- VenclextaTM (venetoclax) - expanded to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in combination with acalabrutinib
Generic Launches
- Pomalyst® (pomalidomide) oral capsule
- Edurant® (rilpivirine) oral tablet
*Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support
.png)
